Harriette R Mogul

Summary

Affiliation: New York Medical College
Country: USA

Publications

  1. doi request reprint Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial
    Harriette R Mogul
    Department of Medicine, Division of Endocrinology, New York Medical College, 490 Munger Pavilion, Valhalla, New York 10595, USA
    J Clin Endocrinol Metab 93:1238-45. 2008
  2. ncbi request reprint Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia
    H R Mogul
    Division of Endocrinology, New York Medical College, Valhalla, New York, USA
    Heart Dis 3:285-92. 2001
  3. ncbi request reprint Syndrome W: a new model of hyperinsulinemia, hypertension and midlife weight gain in healthy women with normal glucose tolerance
    Harriette R Mogul
    Division of Endocrinology, Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
    Heart Dis 4:78-85. 2002
  4. ncbi request reprint Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W)
    Harriette R Mogul
    Divisions of Endocrinology, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Heart Dis 5:384-92. 2003
  5. ncbi request reprint Obesity: new perspectives and pharmacotherapies
    Kerri L Palamara
    Department of Medicine, Harvard Medical School Massachusetts Medical General Hospital, Boston, Massachusetts, USA
    Cardiol Rev 14:238-58. 2006

Collaborators

Detail Information

Publications5

  1. doi request reprint Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial
    Harriette R Mogul
    Department of Medicine, Division of Endocrinology, New York Medical College, 490 Munger Pavilion, Valhalla, New York 10595, USA
    J Clin Endocrinol Metab 93:1238-45. 2008
    ..Its use in PWS adults has been limited by documentation of benefits and risks, as determined by larger multisite studies...
  2. ncbi request reprint Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia
    H R Mogul
    Division of Endocrinology, New York Medical College, Valhalla, New York, USA
    Heart Dis 3:285-92. 2001
    ..The authors concluded that metformin and carbohydrate-modified hypocaloric diet could be an effective novel treatment for long-term weight management in nondiabetic, hyperinsulinemic women...
  3. ncbi request reprint Syndrome W: a new model of hyperinsulinemia, hypertension and midlife weight gain in healthy women with normal glucose tolerance
    Harriette R Mogul
    Division of Endocrinology, Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
    Heart Dis 4:78-85. 2002
    ..The identification of Syndrome W before the onset of overt impaired glucose tolerance, diabetes, or manifestations of coronary artery disease could have important clinical and public health implications for midlife women...
  4. ncbi request reprint Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W)
    Harriette R Mogul
    Divisions of Endocrinology, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Heart Dis 5:384-92. 2003
    ....
  5. ncbi request reprint Obesity: new perspectives and pharmacotherapies
    Kerri L Palamara
    Department of Medicine, Harvard Medical School Massachusetts Medical General Hospital, Boston, Massachusetts, USA
    Cardiol Rev 14:238-58. 2006
    ..Pharmacologic agents are in clinical development that target these substances...